Figure 6. Inhibitor of Upf1, NMDI14, reduces spontaneous seizures after status epilepticus.

(a) Representative western blot showing dose-range finding study on NMDI14 treatment that reduces levels of p-Upf1 in mouse hippocampus. Representative blots have been cropped to reduce unnecessary area. (b) SE was induced in mice by intraamygdala KA and lorazepam (Loraz) was administered after 40 min to curtail seizures and brain injury. Then, 1, 4 and 24 h later NMDI14 was administered ICV to achieve a final ventricular concentration of 50 μM. Spontaneous seizures were counted from day 3 to day 14 after SE using continuous video-EEG monitoring of mice. Original drawing by author Claire Mooney. (c) Graph showing spontaneous seizures recorded in each group. NMDI14 significantly reduced the number of seizures in mice compared to vehicle controls (n = 7/group; 2-way ANOVA with Bonferroni Post-hoc tests **p < 0.01). NMDI14 also reduced the total numbers of seizures had by mice for the duration of the study (d) and the total time spent having seizures (e)(n = 7/group, students t-test *p < 0.05). (f) There was no difference in the average duration of seizures in NMDI14 and vehicle control mice (n = 7/group, Student’s t-test p = 0.5854).